Atom Investors LP Makes New Investment in Celcuity, Inc. $CELC

Atom Investors LP bought a new position in Celcuity, Inc. (NASDAQ:CELC) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 85,583 shares of the company’s stock, valued at approximately $8,536,000. Celcuity accounts for approximately 0.7% of Atom Investors LP’s investment portfolio, making the stock its 24th largest position.

A number of other hedge funds have also added to or reduced their stakes in the business. Ogorek Anthony Joseph NY ADV increased its holdings in Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares in the last quarter. US Bancorp DE increased its holdings in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares in the last quarter. Intech Investment Management LLC increased its holdings in Celcuity by 1.4% in the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after purchasing an additional 183 shares in the last quarter. Aristides Capital LLC increased its holdings in Celcuity by 2.0% in the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after purchasing an additional 303 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the sale, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. This trade represents a 57.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock valued at $5,111,950. Corporate insiders own 13.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CELC. Wells Fargo & Company lowered their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Wolfe Research restated an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a report on Thursday, March 12th. HC Wainwright decreased their price objective on Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Craig Hallum decreased their price objective on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Guggenheim restated a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and a consensus price target of $152.09.

Celcuity Trading Down 1.0%

NASDAQ CELC opened at $87.32 on Wednesday. The company has a market cap of $4.26 billion, a price-to-earnings ratio of -22.39 and a beta of 0.10. Celcuity, Inc. has a 52 week low of $11.27 and a 52 week high of $151.02. The business has a 50 day moving average price of $118.82 and a 200-day moving average price of $111.13. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, equities analysts expect that Celcuity, Inc. will post -3.69 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.